Prior to joining SkinMedica, Ms. Fisher held a number of positions, including Chief Operating Officer of Accorda Therapeutics, Vice President of Strategic Healthcare and Commercial Operations at Cephalon, Inc., and served as a pharmaceutical consultant.
She previously served on the Board of Zeltiq®, prior to its sale to Allergan, and currently serves as a Board Member of OvaScience®. She is active as a member of the Women’s Dermatological Society and the Dermatology Foundation Leader’s Society.
“We are very pleased to have Mary’s knowledge and experience in the skincare market as a part of our Board. I had the opportunity to serve with her as Chairman of both SkinMedica and Colorescience, and know that she can bring both strategic and operational experience to the Board,” said David F. Hale, Executive Chairman of MDRejuvena.
According to Randy Kriech, President and CEO of MDRejuvena, “We look forward to working closely with Mary as we continue to build MDRejuvena into a successful international skincare company.”
MDRejuvena is a private company focused on the licensing, development and commercialization of products for skin health and beauty for the professional market in the U.S. and internationally. The company has developed a skincare line called Rejuvaphyl®, based on a plant-derived ingredient called copper chlorophyllin, which has demonstrated significant skincare benefits. MDRejuvena is the company licensee for North America for pHformula, a scientifically based skincare resurfacing product line. The company also recently introduced the Vivatia® Skin Brightening System for the treatment of hyperpigmentation, one of the largest skincare markets in the world.
SOURCE MDRejuvena, Inc
Powered by WPeMatico